Review: Endothelial cell dysfunction,medial arterial calcification and osteoprotegerin in diabetes

Abstract

Macrovascular complications such as cardiovascular disease and peripheral vascular disease are the leading cause of increased mortality and morbidity, respectively, in patients with diabetes mellitus. The aetiopathogenesis of macrovasculopathy in diabetes is multifactorial and differs in types 1 and 2 diabetes. Endothelial cell dysfunction is an early feature of diabetic vasculopathy and is associated with poor glycaemic control. Chronic hyperglycaemia may promote an adverse vascular milieu leading to early endothelial cell apoptosis, in the long run. The presence of apoptotic cells in the vascular lumen may trigger a cascade of reactions between the promoters and inhibitors of arterial calcification. Medial arterial calcification, a characteristic feature of diabetes, is an important predictor of cardiovascular disease and occurs independently of atherosclerosis. Medial arterial calcification may occur in the presence of normal serum calcium and phosphate levels. Osteoprotegerin is an important modulator of mineral metabolism and manifests its effects in the bone and arteries. It is hypothesised that osteoprotegerin is a key inhibitor of arterial calcification which is released by endothelial cells as a protective measure for survival in adverse conditions. It is a potential risk marker for early identification and monitoring of disturbed mineral metabolism and vasculopathy in diabetes.

Keywords

diabetic vasculopathy endothelial cell dysfunction medial arterial calcification osteoprotegerin RANKL

Get full access to this article

View all access options for this article.

References

Morrish NJ , Wang SL , Stevens LK et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(suppl 2):S14-21.

Most RS , Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals . Diabetes Care 1983;6:87-91.

Soedamah-Muthu SS , Chaturvedi N. , Toeller M. et al. Risk Factors for Coronary Heart Disease in Type 1 Diabetic Patients in Europe: The EURODIAB Prospective Complications Study. Diabetes Care 2004;27:530-7.

Stern MP Diabetes and cardiovascular disease. The ‘common soil’ hypothesis . Diabetes 1995;44:369-74.

Nicolaides E. , Jones CJ Review. Type 2 diabetes: implications for macrovascular mechanics and disease. Br J Diabetes Vasc Dis 2002;2:9-12.

Lehto S. , Niskanen L. , Suhonen M. et al. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:978-83.

Lomashvili KA , Khawandi W. , O’Neill WC Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005;16: 2495-500.

Schalkwijk CG , Stehouwer CD Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci ( Lond) 2005;109:143-59.

Bennett MR , Evan GI , Schwartz SM Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995;95:2266-74.

10.

Gibbons GH , Pratt RE , Dzau VJ Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992;90:456-61.

11.

Fleming I. , Busse R. NO: the primary EDRF. J Mol Cell Cardiol 1999 ;31:5-14.

12.

Schiffrin EL A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol 2001;38 (suppl 2):S3-6.

13.

Hwang SJ , Ballantyne CM , Sharrett AR et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997;96:4219-25.

14.

Miyamoto K. , Ogura Y. , Kenmochi S. , Honda Y. Role of leukocytes in diabetic microcirculatory disturbances. Microvasc Res 1997;54:43-8.

15.

Colwell JA , Nesto RW The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003;26:2181-8.

16.

Ding H. , Triggle CR Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag 2005;1:55-71.

17.

Rudic RD , Sessa WC Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am J Hum Genet 1999;64:673-7.

18.

Corretti MC , Anderson TJ , Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.

19.

Vincent MA , Barrett EJ , Lindner JR et al. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 2003;285:E123-9.

20.

Vervoort G. , Lutterman JA , Smits P. et al. Transcapillary escape rate of albumin is increased and related to haemodynamic changes in normo-albuminuric type 1 diabetic patients. J Hypertens 1999;17(12 Pt 2):1911-6.

21.

Bassenge E. , Zanzinger J. Nitrates in different vascular beds, nitrate tolerance, and interactions with endothelial function. Am J Cardiol 1992;70:23B-9B.

22.

Maiello M. , Boeri D. , Podesta F. et al. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 1992;41:1009-15.

23.

Spranger J. , Kroke A. , Mohlig M. et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003;52:812-7.

24.

Pradhan AD , Manson JE , Rifai N. et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.

25.

Shachor-Meyouhas Y. , Pillar G. , Shehadeh N. Uncontrolled type 1 diabetes mellitus and endothelial dysfunction in adolescents. Isr Med Assoc J 2007;9:637-40.

26.

Kanters SD , Algra A. , Banga JD Carotid intima-media thickness in hyperlipidemic type I and type II diabetic patients. Diabetes Care 1997;20:276-80.

27.

Stehouwer CD , Fischer HR , van Kuijk AW , Polak BC , Donker AJ Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995 ;44:561-4.

28.

Naidoo DP The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovasc J S Afr 2002 ;13:194-9.

29.

Stehouwer C. , Yudkin J. , Fioretto P. , Nosadini R. How heterogeneous is microalbuminuria in diabetes mellitus? The case for ‘benign’ and ‘malignant’ microalbuminuria . Nephrol Dial Transplant 1998;13:2751-4.

30.

Yamagishi S. , Nakamura K. , Jinnouchi Y. et al. Molecular mechanisms for vascular injury in the metabolic syndrome. Drugs Exp Clin Res 2005;31:123-9.

31.

Caballero AE , Arora S. , Saouaf R. et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999 ;48:1856-62.

32.

Meigs JB , Hu FB , Rifai N. , Manson JE Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus . JAMA 2004;291:1978-86.

33.

Wolpert HA , Steen SN , Istfan NW , Simonson DC Insulin modulates circulating endothelin-1 levels in humans. Metabolism 1993;42:1027-30.

34.

Steinberg HO , Brechtel G. , Johnson A. , Fineberg N. , Baron AD Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172-9.

35.

Zeng G. , Nystrom FH , Ravichandran LV et al. Roles for Insulin Receptor, PI3-Kinase, and Akt in Insulin-Signaling Pathways Related to Production of Nitric Oxide in Human Vascular Endothelial Cells. Circulation 2000;101:1539-45.

36.

Vicent D. , Ilany J. , Kondo T. et al. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J Clin Invest 2003;111:1373-80.

37.

Hermann C. , Assmus B. , Urbich C. et al. Insulin-Mediated Stimulation of Protein Kinase Akt: A Potent Survival Signaling Cascade for Endothelial Cells. Arterioscler Thromb Vasc Biol 2000;20:402-9.

38.

Cersosimo E. , DeFronzo RA Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006;22:423-36.

39.

Steinberg HO , Baron AD Vascular function, insulin resistance and fatty acids. Diabetologia 2002;45:623-34.

40.

McMillan DE Disturbance of serum viscosity in diabetes mellitus . J Clin Invest 1974;53:1071-9.

41.

Cagliero E. , Maiello M. , Boeri D. , Roy S. , Lorenzi M. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 1988 Aug;82:735-8.

42.

Graier WF , Grubenthal I. , Dittrich P. et al. Intracellular mechanism of high D-glucose-induced modulation of vascular cell proliferation. Eur J Pharmacol 1995;294:221-9.

43.

McMillan DE Increased levels of acute-phase serum proteins in diabetes. Metabolism 1989;38:1042-6.

44.

Baumgartner-Parzer SM , Wagner L. , Pettermann M. et al. Modulation by high glucose of adhesion molecule expression in cultured endothelial cells . Diabetologia 1995;38:1367-70.

45.

Baumgartner-Parzer SM , Wagner L. , Pettermann M. et al. High-glucose-triggered apoptosis in cultured endothelial cells. Diabetes 1995;44:1323-7.

46.

Lum H. , Roebuck KA Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 2001;280:C719-41.

47.

Ritthaler U. , Deng Y. , Zhang Y. et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995;146:688-94.

48.

O’Driscoll G. , Green D. , Maiorana et al. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999;33:1506-11.

49.

Vattikuti R. , Towler DA Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab 2004;286: E686-96.

50.

Nicholls SJ , Tuzcu EM , Kalidindi S. et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008;52:255-62.

51.

Shanahan CM , Cary NRB , Salisbury JR et al. Medial localization of mineralization-regulating proteins in association with Monckebergæs sclerosis: evidence for smooth muscle cell-mediated vascular calcification . Circulation 1999;100:2168-76.

52.

Secchiero P. , Corallini F. , Pandolfi A. et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006;169:2236-44.

53.

Schoppet M. , Al- Fakhri N. , Franke FE et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg’s sclerosis and atherosclerosis . J Clin Endocrinol Metab 2004;89:4104-12.

54.

Guzman RJ Clinical, cellular, and molecular aspects of arterial calcification . J Vasc Surg 2007;45(suppl A):A57-63.

55.

Chen PL , Easton A. Apoptotic phenotype alters the capacity of tumor necrosis factor-related apoptosis-inducing ligand to induce human vascular endothelial activation . J Vasc Res 2008;45:111-22.

56.

Collin-Osdoby P. , Rothe L. , Anderson F. et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis . J Biol Chem 2001;276:20659-72.

57.

Hayden MR , Tyagi SC , Kolb L. et al. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005;4:4.

58.

Csiszar A. , Smith KE , Koller A. et al. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation 2005;111:2364-72.

59.

Shao JS , Cai J. , Towler DA Molecular mechanisms of vascular calcification: lessons learned from the aorta . Arterioscler Thromb Vasc Biol 2006;26:1423-30.

60.

Al-Aly Z. , Shao JS , Lai CF et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2007;27:2589-96.

61.

Sugitani H. , Wachi H. , Mecham RP , Seyama Y. Accelerated calcification represses the expression of elastic fiber components and lysyl oxidase in cultured bovine aortic smooth muscle cells. J Atheroscler Thromb 2002;9:292-8.

62.

Trion A. , van der LA Vascular smooth muscle cells and calcification in atherosclerosis . Am Heart J 2004;147:808-14.

63.

Johnson K. , Polewski M. , van Etten D. , Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/- mice. Arterioscler Thromb Vasc Biol 2005;25:686-91.

64.

Demetriou M. , Binkert C. , Sukhu B. et al. Fetuin/alpha 2-HS glycoprotein is a transforming growth factor-beta type ii receptor mimic and cytokine antagonist . J Biol Chem 1996 ;271:12755-61.

65.

Watson KE , Bostrom K. , Ravindranath R. et al. TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest 1994 ;93:2106-13.

66.

Schoppet M. , Preissner KT , Hofbauer LC RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.

67.

Malyankar UM , Scatena M. , Suchland KL et al. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 2000;275:20959-62.

68.

Shin JY , Shin YG , Chung CH Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006;29:1664-6.

69.

O’Rourke RA , Brundage BH , Froelicher VF et al. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease . Circulation 2000;102:126-40.

70.

Arad Y. , Spadaro LA , Goodman K. et al. Predictive value of electron beam computed tomography of the coronary arteries. 19-month follow-up of 1173 asymptomatic subjects. Circulation 1996;93:1951-3.

71.

Waugh N. , Black C. , Walker S. et al. The effectiveness and cost-effectiveness of computed tomography screening for coronary artery disease: systematic review. Health Technol Assess 2006;10:iii-x,1.